The Emergence of Modern Cancer Immunotherapy

This publication has 14 references indexed in Scilit:

• Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2
  Annals of Surgical Oncology, 2005
• Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
  Journal of Clinical Oncology, 2005
• Cancer immunotherapy: moving beyond current vaccines
  Nature Medicine, 2004
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
  Proceedings of the National Academy of Sciences, 2003
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
  Science, 2002
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2
  Annals of Surgery, 1998
• Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
  New England Journal of Medicine, 1988
• High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer
  JAMA, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985